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The effect of dexmedetomidine 
on cerebral perfusion and oxygenation 
in healthy piglets with normal 
and lowered blood pressure anaesthetized 
with propofol-remifentanil total intravenous 
anaesthesia
Mai Louise Grandsgaard Mikkelsen1*, Rikard Ambrus2, Rune Rasmussen3, James Edward Miles1, 
Helle Harding Poulsen1, Finn Borgbjerg Moltke4,5 and Thomas Eriksen1
Abstract 
Background: During anaesthesia and surgery, in particular neurosurgery, preservation of cerebral perfusion and 
oxygenation (CPO) is essential for normal postoperative brain function. The isolated effects on CPO of either indi-
vidual anaesthetic drugs or entire anaesthetic protocols are of importance in both clinical and research settings. 
Total intravenous anaesthesia (TIVA) with propofol and remifentanil is widely used in human neuroanaesthesia. In 
addition, dexmedetomidine is receiving increasing attention as an anaesthetic adjuvant in neurosurgical, intensive 
care, and paediatric patients. Despite the extensive use of pigs as animal models in neuroscience and the increasing 
use of both propofol-remifentanil and dexmedetomidine, very little is known about their combined effect on CPO 
in pigs with uninjured brains. This study investigates the effect of dexmedetomidine on CPO in piglets with normal 
and lowered blood pressure during background anaesthesia with propofol-remifentanil TIVA. Sixteen healthy female 
Danish pigs (crossbreeds of Danish Landrace, Yorkshire and Duroc, 25–34 kg) were used. Three animals were subse-
quently excluded. The animals were randomly allocated into one of two groups with either normal blood pressure 
(NBP, n = 6) or with induced low blood pressure (LBP, n = 7). Both groups were subjected to the same experimental 
protocol. Intravenous propofol induction was performed without premedication. Anaesthesia was maintained with 
propofol-remifentanil TIVA, and later supplemented with continuous infusion of dexmedetomidine. Assessments of 
cerebral perfusion obtained by laser speckle contrast imaging (LSCI) were related to cerebral oxygenation measures 
 (PbrO2) obtained by an intracerebral Clark-type Licox probe.
Results: Addition of dexmedetomidine resulted in a 32% reduction in median  PbrO2 values for the LBP group 
(P = 0.03), but no significant changes in  PbrO2 were observed for the NBP group. No significant changes in LSCI 
readings were observed in either group between any time points, despite a 28% decrease in the LBP group follow-
ing dexmedetomidine administration. Caval block resulted in a significant (P = 0.02) reduction in median MAP from 
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Background
During anaesthesia and surgery, in particular neurosur-
gery, preservation of cerebral perfusion and oxygena-
tion (CPO) is essential for normal postoperative brain 
function [1, 2]. Choice of anaesthetic protocol, cerebral 
pathology, the patient’s haemodynamic stability, and their 
interaction can influence the CPO response [3, 4]. Studies 
in rabbits have shown significant differences in the cer-
ebral perfusion responses to anaesthetics in normal and 
injured brains [5, 6], so CPO results from neurocritical 
studies cannot be definitively translated to patients with 
normal brain physiology. In humans over 60 years, both 
short and long-term postoperative cognitive disorders 
can be seen following anaesthesia in relation to both non-
cardiac and non-neurologic major surgery [7]. In this 
context, understanding of the anaesthetic effect on CPO 
in the healthy brain must be considered a prerequisite for 
understanding the pathology and anaesthetic influence 
in the diseased brain [3]. Total intravenous anaesthesia 
(TIVA) with a combination of propofol and remifentanil 
is extensively used during ambulatory surgery, paediatric 
surgery and neurosurgery in humans [8–11]. This com-
bination of anaesthetics has several characteristics that 
preserve cerebrovascular reactivity to  CO2 and autoregu-
latory mechanisms [11–14], and can be a suitable basis 
anaestesia in experimental CPO studies.
In this context,  alpha2-adrenergic-agonists, in particu-
lar dexmedetomidine, are receiving increasing attention 
as sedatives and as anaesthetic adjuvants for neurosur-
gical, intensive care and paediatric human patients [15–
19]. In veterinary anaesthesia, α2-adrenergic-agonists 
have been used widely for sedation and as part of general 
anaesthesia for many years [20–22]. Dexmedetomidine 
potentiates propofol and opioids and has been shown to 
reduce cerebral blood flow (CBF), possess neuroprotec-
tive properties, and to be suitable for continuous infusion 
in TIVA and conscious sedation in humans [17, 23–26]. 
In spite of this, the use of dexmedetomidine in patients 
with cardiovascular disease or cerebral pathology is still 
debated primarily with regards to systemic hypotension, 
bradycardia and potential cerebral vasoconstriction [27].
Both in human and veterinary anaesthesia it is recom-
mended that these patients need individually tailored 
neuroanaesthesia in order to maintain optimal CPO [21, 
28, 29]. Due to ethical concerns regarding clinical stud-
ies in humans, strategies for individually tailored neu-
roanesthesia are often explored in experimental animals. 
Porcine animal models are well described in neurosci-
ence and are often preferred over smaller animals due to 
the closer resemblance to the human brain in anatomy, 
growth, and development [30]. Despite the extensive use 
of pigs as animal models and the abundant use of propo-
fol-remifentanil in human neuroanaesthesia and dex-
medetomidine in veterinary anaesthesia in general, very 
little is known about their combined effect on CPO in 
anaesthetized pigs with uninjured brains. Guidelines for 
anaesthesia in experimental animal trials studying CPO 
are, therefore, poorly established [31].
The objective of this study was to investigate the effect 
of dexmedetomidine on CPO in piglets with normal and 
lowered blood pressure during background anaesthesia 
with propofol-remifentanil TIVA.
Methods
Study design
This study was designed as a non-blinded, two-arm par-
allel group, experimental animal trial. Animals were 
allocated into one of two groups with either normal 
blood pressure (NBP) or with low blood pressure (LBP) 
by a computerized lottery draw randomization schedule 
(www.random.org). Figure 1 illustrates the experimental 
protocol; additional data will be reported separately. Full 
details and data regarding the entire study are presented 
in Additional file  1. The Danish Animal Experiments 
Inspectorate approved the study (licence no. 2013-15-
2934-00909), and all procedures were performed in 
accordance with national legislation and The Council of 
Europe Convention ETS 123. All animals were acquired 
through, and housed by, the Department of Animal 
Experimental Medicine at the University of Copenha-
gen. The piglets were inspected and considered healthy 
on reception at the housing facility by the veterinarian 
68 mmHg (range 63–85) at PCB to 58 mmHg (range 53–63) in the LBP group, but no significant differences in either 
 PbrO2 or LSCI were observed due to this intervention (P = 0.6 and P = 0.3 respectively).
Conclusions: Addition of dexmedetomidine to propofol-remifentanil TIVA resulted in a significant decrease in 
cerebral oxygenation  (PbrO2) measurements in piglets with lowered blood pressure. Cerebral perfusion (LSCI) did not 
decrease significantly in this group. In piglets with normal blood pressure, no significant changes in cerebral perfusion 
or oxygenation were seen in response to addition of dexmedetomidine to the background anaesthesia.
Keywords: Cerebral perfusion, Cerebral oxygenation, Swine, Propofol, Remifentanil, Dexmedetomidine, Laser speckle 
contrast imaging, Licox
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responsible for the trial. The piglets were allowed to accli-
matize to the facility for at least 1 week before the experi-
ment began. The piglets were housed in groups of 3–4 (in 
the same group as they arrived) in cement-floored pens 
measuring 5.5 m2 with fine wood chip and straw bedding. 
Environmental enrichment with toys and music were 
supplied through the daytime. A 7:17 light:dark cycle was 
used and the room temperature were kept at 19–20  °C. 
The piglets were fed a commercial finisher diet (Svine-
foder 5, Nordsjællands Andels Grovvareforening Amba, 
Helsinge, Denmark), given according to weight twice 
daily (0800 and 1500), and the piglets had free access to 
water. Food, but not water, was withheld overnight prior 
to the experiment.
The results of this study are reported in accordance 
with ARRIVE guidelines [32].
Animals and anaesthesia
Sixteen healthy female Danish pigs (crossbreeds of 
Danish Landrace, Yorkshire and Duroc) with a median 
weight of 27 kg (range 25–34) were used. Venous access 
for propofol induction was secured the day prior to the 
experiment under sedation (see Additional file 2), using 
catheters  (Arrow® arterial catheterization set, SAC-
00822: 20  ga  ×  8  cm, Teleflex, Ireland) placed in the 
auricular vein of both ears.
All 16 animals were subjected to the same anaesthetic 
protocol: no premedication was given on the day of the 
experiment. General anaesthesia was induced by an 
intravenous (iv) bolus of 4–8  mg/kg propofol (10  mg/
ml Propofol “B. Braun”, B. Braun Melsungen, Germany), 
while the animals were still in their pen to minimise 
stress. After transport to the experimental area, they 
were placed in ventral recumbency on a padded operat-
ing table and mechanically ventilated following endotra-
cheal intubation. A mechanical ventilator (Bag-in-bottle 
respirator, Type no. 86,298, Dameca A/S, Roedovre, Den-
mark) was used to maintain end tidal  CO2  (EtCO2) 
between 35 and 50  mmHg by regulation of the respira-
tion rate (RR) (11–21/min) and tidal volume (10–15 ml/
kg) to keep the inflation pressure below 20 cm  H2O using 
an inspiration:expiration ratio of 1:2 and a set PEAK 
pressure of 20  cm  H2O. The circuit used was a co-axial 
circle-system.
General anaesthesia was maintained by propofol 
(10  mg/ml Propofol “B. Braun”, B. Braun Melsungen, 
Germany) and remifentanil (1  mg/ml  Ultiva®, GlaxoS-
mithKline Pharma, Denmark, diluted with sterile water 
to 100 µg/ml) TIVA using separate syringe pumps (Ter-
umo, Terufusion Syringe Pump TE-331, Belgium). Doses 
were based on our pilot studies, with a propofol dose 
range of 12–20  mg/kg/h and a remifentanil dose range 
of 20–45  µg/kg/h. Doses were individually regulated to 
accomplish unresponsiveness to noxious stimuli (dew-
claw pinching). Propofol doses were adjusted to control 
anaesthetic depth (assessed as lack of movement) and 
remifentanil doses were adjusted to eliminate responses 
to noxious stimuli. Propofol and remifentanil doses were 
not altered after animal preparation was completed. Dex-
medetomidine (0.5  mg/ml  Dexdomitor®, Orion Pharma 
Animal Health, Sollentuna, Sweden) was added following 
time point PR2 (Fig. 1) with an iv bolus of 1 µg/kg admin-
istrated over 10 min, followed by a fixed dose of 0.7 µg/
kg/h iv (5 µg/ml solution).
Surgical preparation and instrumentation
All invasive procedures were conducted after local infil-
tration with a mixture of lidocaine (20 mg/ml  Xylocain® 
AstraZeneca, Copenhagen, Denmark) and bupiv-
acaine (5  mg/ml  Marcain® AstraZeneca, Copenhagen, 
Denmark).
A circular craniotomy (20–30  mm) was performed 
over the right parietal lobe with a 5  mm craniotome 
(Midas Rex, Medtronic, Heerlen, The Netherlands). After 
dural excision, cerebral perfusion was directly measured 
semi-quantitatively (laser speckle perfusion units—
LSPU) using a laser speckle contrast imaging (LSCI) 
camera (moorFLPI-2, Moor Instruments, Devon, UK) 
placed perpendicular to and 25  cm from the region of 
interest. The position of the head of the animal remained 
unchanged throughout the experiment. An intracerebral 
Clark-type probe connected to a  Licox® Brain Tissue 
Oxygen Monitoring System (Integra LifeSciences, New 
Jersey, USA) was placed in the periphery of the crani-
otomy, in white matter 25  mm subdurally and secured 
Fig. 1 Experimental design. The experimental flow for the two 
groups (NBP normal blood pressure group, LBP low blood pressure 
group), with the median duration of each period (min–max range in 
brackets). Key time points are marked (arrows), and corresponding 
time points between groups are joined by dotted lines. PCB Pre-caval 
Block, PR-1 Propofol-remifentanil experimental start, PR-2 Propofol-
remifentanil end–immediately prior to dexmedetomidine infusion, 
PR-D following dexmedetomidine infusion
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to the craniotomy edge with bone wax for recording of 
cerebral oxygenation (partial pressure of oxygen in brain 
tissue—PbrO2).
The femoral artery was cannulated  (Arrow® arterial 
catheterization set, SAC-01620: 20  ga  ×  16  cm, Tel-
eflex, Ireland) for invasive blood pressure monitoring 
and intermittent blood collection for blood gas analysis 
(GEM Premier 3000, Instrumentation Laboratory, Lex-
ington MA, USA). The femoral vein was cannulated for 
placement of an 8 French balloon-tipped catheter (MILA 
International Inc., Kentucky, USA) in all animals but only 
used for induction of caval block in the LBP group. The 
catheter was premeasured to position the balloon in the 
caudal vena cava just caudal to the heart. Caval block was 
induced by injecting sterile isotonic NaCl into the cath-
eter balloon to partially obstruct the vena cava.
A urinary catheter with a closed collecting bag was 
placed to prevent bladder distension. Fluids were admin-
istered throughout the experiment at 2.5 ml/kg/h iv (glu-
cose 50 mg/ml, B. Braun Melsungen. Germany).
A multiparametric bedside monitor (Datex-Ohmeda 
S/5, Helsinki, Finland) was used to record cardiovascu-
lar and pulmonary variables every 30 s: data were trans-
ferred to a personal computer using Datex-Ohmeda 
S/5™ Collect software (GE Healthcare, Helsinki, Fin-
land). Recorded variables were pulse rate, invasive mean 
arterial blood pressure (MAP), body temperature by 
oesophageal probe, fraction of inspired oxygen  (FiO2) 
and  EtCO2. The electrocardiogram and peripheral oxy-
gen saturation by pulse oximetry  (SpO2) measured on 
the tail or the lower lip were monitored for continuous 
assessment.
Experimental protocol
After instrumentation the Licox probe was equilibrated 
for up to 2  h or until  PbrO2 exceeded 25  mmHg before 
baseline data were collected (PR-1–NBP and PCB–
LBP) for all animals (Fig.  1). In the LBP group, MAP 
was then lowered by caval block until a stable MAP 
of 50–60  mmHg was reached, and data recording was 
repeated (PR1–LBP). The caval block was maintained 
unadjusted throughout the experiment. Data were col-
lected at all key time points (Fig. 1), with time point PRD 
placed following 30  min of dexmedetomidine infusion. 
Arterial blood gas samples for analysis of pH,  PaCO2, 
 PaO2, bicarbonate  (HCO3−), base excess (BE), blood glu-
cose, lactate, total haemoglobin concentration (THbc) 
and haematocrit (Hct) were obtained at each time point.
Between PR-1 and PR-2, and following PRD, vasopres-
sor challenges were made using norepinephrine and phe-
nylephrine. A 30-min washout period was allowed before 
time point PR2. Data collected during these periods of 
vasopressor challenge will be reported separately.
At the end of the experiments, the animals were eutha-
nized with pentobarbital sodium iv (400 mg/ml, Euthasol 
vet., Virbac, Denmark).
Statistics
Statistical per protocol analysis was performed using 
SPSS 24.0 software (IBM® SPSS® Statistics for Mac, IBM 
Corp. ©, Armonk, NY, USA), and  Microsoft®  Excel® for 
Mac 2011 version 14.3.9 (2010 Microsoft Corporation). 
Normal distribution of data could not be assumed due 
to the sample size and non-parametric statistical analy-
ses were used. Data are reported as median values with 
either range (min–max) or 95% confidence intervals (95% 
CI) obtained using Hodges–Lehmann estimates given 
where appropriate. P-values ≤0.05 were considered sta-
tistically significant. Comparisons between time-points 
PCB and PR-1 (LBP group) were made using Wilcoxon’s 
signed rank test. Comparisons between LBP and NBP 
were made using the independent-samples median test. 
Comparisons of primary outcome measures  (PbrO2 and 
LSPU) and secondary explanatory variables (haemody-
namics and blood gas) across time points PR-1 to PR-2 
and PR-2 to PRD were made using Friedman’s ANOVA 
with post hoc Bonferroni corrected pairwise comparisons 
when Friedman’s ANOVA was significant. Comparisons 
between selected time point medians and literature-
derived cut-off values were made using the one-sided, 
one-sample Wilcoxon signed rank test to determine if 
medians lay above the cut-off. A sample size of 16 ani-
mals, divided into two groups of 8, was calculated using 
conservative estimates based on earlier studies [33] with 
expected power of 80% in detecting a minimum of 30% 
difference in MAP with a two-tailed significance level of 
5% after supplementation of dexmedetomidine.
Results
All 16 animals completed the experimental protocol. 
Data from three (NBP group n = 2, LBP group n = 1) pig-
lets were excluded from analysis. One piglet developed 
signs of brain oedema with a severe reduction in CPO 
following craniotomy (LBP group). In the NBP group, 
one pig had persistently and unexplainably high pulse 
rate,  EtCO2,  PaCO2 and a low pH, which were expected 
to produce an atypical CPO response. The other pig was 
excluded due to technical difficulties.
Anaesthesia time, preparation time, anaesthetic doses 
and baseline CPO measurements were not statistically 
different between NBP and LBP groups. Both groups 
reached normal cerebral oxygenation levels following 
animal preparation and equilibration of the Licox probe 
(Table 1) [8, 34].
Caval block resulted in a significant (P = 0.02) reduc-
tion in median MAP from 68  mmHg (range 63–85) at 
Page 5 of 13Mikkelsen et al. Acta Vet Scand  (2017) 59:27 
PCB to 58 mmHg (range 53–63) at PR1 in the LBP group 
(Fig. 2), but no significant differences in either  PbrO2 or 
LSPU were observed due to this intervention (P  =  0.6 
and P = 0.3 respectively) (Fig. 3).
A significant difference in the intra-group distributions 
of  PbrO2 readings was observed between time points 
PR-1, PR-2 and PRD for group LBP (P =  0.05), but not 
for NBP (P =  0.5). Post-hoc Bonferroni corrected pair-
wise comparisons showed a significant (P  =  0.03) 32% 
reduction in median  PbrO2 values (−7  mmHg, 95% CI 
−2; −17) for LBP between PR-2 and PRD. Median  PbrO2 
readings for both groups were significantly (P  <  0.03, 
one-tailed) higher than the threshold value of 15 mmHg 
for cerebral ischaemia at all time points [35, 36]. No sig-
nificant changes in the distributions of LSPU readings 
were observed for either group between time-points 
PR-1, PR-2 and PRD, despite a 28% fall in LSPU values 
(median difference −186 LSPU, 95% CI −7; −478) in the 
LBP group following dexmedetomidine administration. 
No significant between-group differences were detected 
at any time point.
In the LBP group, median MAP was significantly 
(P  <  0.03, one-tailed) greater than the lower limit for 
cerebral autoregulation (LLCA) of 50 mmHg at all time 
points except PRD, but in the NBP group median MAP 
was consistently above this limit (P = 0.01, one-tailed).
No statistically significant intra-group changes in MAP 
over time points PR-1, PR-2 and PRD were observed, 
despite a trend to an increase from PR-1 to PR-2 (median 
6 mmHg, 95% CI −10; 13 and 9 mmHg, 95% CI −4; 25 
for LBP and NBP, respectively) and a decrease from 
PR-2 to PRD (median −10 mmHg, 95% CI −1; −22 and 
−6  mmHg, 95% CI −18; 5). This corresponds to a 19% 
reduction of median MAP in the LBP group following 
dexmedetomidine infusion. At all time points, median 
MAP values were significantly (P =  0.03) lower for the 
LBP group than for the NBP group, with median differ-
ences of 8−25 mmHg.
In the LBP group, there was a significant (P  =  0.02) 
increase in median pulse rate following initiation of caval 
block (median increase 10, 95% CI 2; 47). No significant 
differences were found between time points PR1, PR2 and 
PRD for either group, or between groups at any time point.
For both LBP and NBP groups, a significant (P = 0.02 
for both) intra-group change in  EtCO2 distributions was 
observed. Pairwise testing showed a significant decrease 
in median values of 5  mmHg (95% CI 2; 11) for LBP 
(P = 0.02) and 4 mmHg (95% CI 2; 5) for NBP (P = 0.01) 
between time points PR-2 and PR-D. This was associated 
in the LBP group, but not the NBP group, with a signif-
icant (P =  0.03) decrease in median  PaCO2 readings of 
5 mmHg (95% CI 2.5; 9) from PR-2 to PR-D. A trend to 
increasing  EtCO2 levels in the LBP group between PR-1 
and PR-2 was associated with a significant (P  =  0.03) 
increase in  PaCO2 levels (median increase 6, 95% CI 1; 
11). Median  PaCO2 values were 0-3.5 mmHg higher, and 
median  EtCO2 values 0.6–2  mmHg higher, in the LBP 
group than the NBP group, but this was not statistically 
significant at any time point.
Median body temperature was 0.8–1.5 °C higher in the 
LBP group than the NBP group across time points PR-1, 
PR-2 to PRD, but this was not statistically significant 
(Table 2). No significant intra-group changes in distribu-
tion were observed.
Additional physiological parameters are reported in 
Table 2.
Discussion
The key finding in this study was the significant fall in 
cerebral oxygenation following supplementation with 
dexmedetomidine to propofol-remifentanil TIVA in pig-
lets with lowered blood pressure but not in piglets with 
normal blood pressure.
Cerebral perfusion and oxygenation response 
to dexmedetomidine
In the piglets with normal blood pressure neither 
cerebral perfusion nor oxygenation changed signifi-
cantly after addition of dexmedetomidine to propofol-
remifentanil TIVA. This supports previous findings that 
Table 1 Baseline data. Data were recorded at time points PR1 (normal blood pressure group—NBP) and PCB (low blood 
pressure group—LBP), prior to induction of caval block in the LBP group
Data are reported as median and range (min–max)
PbrO2, partial pressure of oxygen in brain tissue; LSPU, laser speckle perfusion unit
Propofol-remifentanil 1 (PR-1) Pre-caval block (PCB) P value
NBP (n = 6) LBP (n = 7)
Preparation time (min) 227 (175–284) 226 (147–240) 0.63
Propofol dose (mg/kg/h) 15 (12–20) 15 (12–18) 1.00
Remifentanil dose (µg/kg/h) 30 (20–40) 25 (20–45) 0.53
Cerebral oxygenation  (PbrO2 mmHg) 25.6 (19.9–55.7) 29.6 (20.3–32.2) 0.45
Cerebral perfusion (LSPU) 1033.9 (730.4–1251.5) 1090.7 (845.5–1762.0) 0.53
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dexmedetomidine does not affect  PbrO2 in patients with 
normal blood pressure and healthy brains [19] or patients 
with neurovascular injuries [43].
Cerebral oxygenation measured by Licox decreased 
after dexmedetomidine supplementation in piglets with 
lowered blood pressure. The normal range for  PbrO2 is 
25–30  mmHg in pigs [34], which is comparable to the 
human normal range of 25–50  mmHg [8]. Our median 
baseline results were within these limits. Caval block 
in the LBP group produced a significant decrease in 
MAP, but not in the CPO measures. The lack of CPO 
response to induced hypotension was expected, since 
the caval block was adjusted to a MAP target range of 
50–60 mmHg in order to keep the blood pressure within 
the standard range of cerebral autoregulation [12]. The 
subsequent significant 32% decrease in cerebral oxygen-
ation in the LBP group is most likely a response to the 
additive effect of dexmedetomidine to propofol-remifen-
tanil TIVA.
Cerebral oxygenation measured as partial pressure of 
oxygen in brain tissue  (PbrO2) is believed to reflect fac-
tors affecting both oxygen cerebral tissue diffusion as well 
as CBF [35] and may thus be regarded as an indicator of 
the combined effect of cerebral perfusion and metabo-
lism [44]. Dexmedetomidine has been shown to decrease 
CBF in both human [25, 26, 45, 46] and animal studies 
[47, 48] but did not reduce  PbrO2 in a series of five sur-
gical patients with neurovascular injuries [43]. The same 
studies conclude that the reduction in CBF is not cou-
pled to a decrease in cerebral metabolic rate. The influ-
ence of dexmedetomidine on CBF is believed to be due 
to lowering of systemic blood pressure through centrally 
α2A-mediated sympatholysis [49, 50] or by α2B-mediated 
cerebral vascular smooth muscle constriction [26, 51] as 
well as lowering cerebral metabolism by lowering brain 
activity [26]. The overall clinical effect reflects the sum of 
these central and peripheral effects, and is related to the 
doses used [52, 53].
In this study, cerebral perfusion was evaluated by LSCI. 
Laser speckle contrast imaging is able to assess real-
time cerebral perfusion [54–56], and in piglets LSCI has 
been successfully used to evaluate changes in pial arteri-
olar blood flow [57]. Our results disagree with previous 
studies [25, 26, 45–48], since addition of dexmedeto-
midine did not produce significant changes in cerebral 
perfusion in either the NBP or the LBP group. The sig-
nificant decrease found in  PbrO2 in the latter group, could 
not be related to a statistically significant decrease in 
LSPU measures, despite a decrease in 6 out of 7 piglets 
resulting in a 30% reduction of median LSPU. A post hoc 
power analysis (G*power for Mac, version 3.19.2) based 
on our LSPU data revealed a low power (0.47), increas-
ing the risk of Type II error, so that an effect on cerebral 
perfusion by dexmedetomidine might have been falsely 
rejected. Since we did not assess cerebral metabolism, we 
cannot conclude if the significant  PbrO2 reduction was 
related to reduced CBF or to a lack of reduction in cer-
ebral metabolism.
All  PbrO2 measurements were significantly higher than 
15 mmHg, which may be used as a threshold value below 
which the risks of cerebral ischaemia [35], and mortality 
may increase [36].
The clinical significance of reduced cerebral oxygena-
tion will probably depend on the  PbrO2 prior to dex-
medetomidine supplementation and to the integrity 
of cerebral autoregulatory mechanisms, as well as to 
haemodynamic stability. Therefore, particular attention 
should be directed towards paediatric, neurosurgical, and 
intensive care patients, which are patient groups in which 
the use of dexmedetomidine has gained increasing inter-
est in recent years [15, 17, 45, 58, 59].
Haemodynamic responses
The baseline MAP was comparable to findings in other 
studies based on propofol-remifentanil in pigs [60], even 
though it was relatively low. The significant difference in 
MAP between the NBP and the LBP group was conse-
quently clinically small, but the difference was consistent 
and statistically significant throughout the experiment.
The MAP in the NBP group remained well within nor-
mal limits and statistically significantly exceeded the 
LLCA at all time points, indicating that in piglets with 
normal blood pressure propofol-remifentanil TIVA both 
with and without dexmedetomidine provides a haemo-
dynamically stable anaesthesia (Fig. 2). In contrast, in the 
LBP group following addition of dexmedetomidine the 
median MAP no longer significantly exceeded the LLCA. 
Although studies on propofol-remifentanil-dexmedetomi-
dine anaesthesia in pigs are not available, Sano et al. [33] 
showed a significant decrease in MAP with addition of the 
(See figure on previous page.) 
Fig. 2 Boxplots of mean arterial blood pressure and end-tidal carbon dioxide at the different timepoints. Box and whisker plots showing median 
(line), interquartile range (shaded) and outliers (circles) for mean arterial pressure (in mmHg) (a), and end-tidal carbon dioxide  (ETCO2, in mmHg) (b) 
in the normal blood pressure group (NBP) and low blood pressure group (LBP). Whiskers extend a maximum of 1.5× the interquartile range. The 
lower mean arterial pressure limit for cerebral autoregulation is shown (dashed line). Experimental timepoints: PCB pre-caval block, PR-1 initial base-
line for propofol-remifentanil TIVA, PR-2 immediately before dexmedetomidine administration, PRD following propofol-remifentanil-dexmedetomi-
dine TIVA. Significant differences from either the autoregulation limit (vertical bars) or between timepoints (horizontal bars) are shown
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same dose of dexmedetomidine to background anaesthesia 
of propofol alone, in contrast to our findings in the NBP 
group. The observed 19% decrease in MAP after addition 
of dexmedetomidine in the LBP group, even though not 
statistically significant, corresponds to previous reports 
in humans [50, 61, 62] and is mediated by activation of 
central α2-adrenergic receptors and subsequent attenu-
ation of sympathetic activity [63]. Thus, individuals with 
compromised cardiovascular function may be at risk of 
experiencing an additional decrease in MAP when dex-
medetomidine is added to propofol-remifentanil TIVA, 
which may be a concern in both experimental and clinical 
settings.
The significant increase in pulse rate between PCB 
and PR-1 observed in the LBP group likely repre-
sents an intact sympathetic response during propo-
fol-remifentanil TIVA. The lack of pulse increase in 
response to the apparent decrease in MAP between 
PR-2 and PRD could reflect the sympatholytic effect of 
dexmedetomidine.
Background physiology
Mild to moderate hypercapnia was observed in both NBP 
and LBP groups, with minimal and statistically insignifi-
cant inter-group differences. Previous studies suggest 
that even small increases in  PaCO2 can increase cerebral 
blood flow [26]. Mild compensated respiratory acidosis 
was observed in both groups until PR-1. However, the 
slightly higher  PaCO2 levels in the LBP group and the 
mild acidosis was more evident in the LBP group com-
pared to the NBP group at time point PR-2, but this did 
not appear to have any significant consequences for cer-
ebral perfusion in our study.
Throughout the study, both THbc and haematocrit 
were below the reference range for adult pigs, but this is 
expected in piglets of 2–3 months of age [64]. In the LBP 
group both parameters increased significantly from PCB 
to PR1 and PR1 to PR2, but the amounts were small and 
not considered clinically relevant to this study.
Strengths and limitations
The model, experimental design and sample size in this 
study, were selected to investigate the effects of both 
dexmedetomidine and hypotension and to follow the 
3 Rs tenet for the use of animals in research in the best 
possible way [65]. Some power was lost due to the post 
hoc exclusion of three animals.
The porcine model presented here was technically fea-
sible, effectively inducing hypotension, which persisted 
throughout an experimental time period exceeding 7  h. 
The craniotomy was technically simple, but required 
careful preparation and the only complication encoun-
tered was a small haematoma in one animal. This com-
plication represents the main methodological concern 
about LSCI recording in this model.
Avoiding premedication on the experimental day elimi-
nates interference from other drugs on the effects of 
propofol, remifentanil and dexmedetomidine. Additional 
sedative or anaesthetic drugs risk contaminating cerebral 
outcome measures in animal experiments unless proper 
consideration is given to sufficient washout periods and 
drug interactions [8, 66–68].
In terms of neural maturity, this animal model best 
mirrors cerebral haemodynamics in children of approxi-
mately 10 months of age [69, 70] and translation to other 
age groups should be made with caution [71, 72].
We cannot exclude a potential influence from the vaso-
pressor challenges performed on these animals, since 
we have not included a vasopressor-free control group. 
However, we used an extended washout period after 
vasopressor treatment (see Additional file 1), and no sig-
nificant differences were noted for the primary outcomes 
measures of CPO between PR-1 and PR-2.
Conclusions
Addition of dexmedetomidine to propofol-remifentanil 
TIVA resulted in a significant decrease in cerebral oxy-
genation  (PbrO2) measurements in piglets with low-
ered blood pressure. Cerebral perfusion (LSCI) did not 
decrease significantly in this group. In piglets with nor-
mal blood pressure, no significant changes in cerebral 
perfusion or oxygenation were seen in response to addi-
tion of dexmedetomidine to the background anaesthesia. 
The results of this study suggest that caution is war-
ranted when using dexmedetomidine as a supplement to 
propofol-remifentanil TIVA in patients with low blood 
(See figure on previous page.) 
Fig. 3 Boxplots of cerebral perfusion and oxygenation at the different time points. Box and whisker plots showing median (line), interquartile range 
(shaded) and outliers (circles) for partial pressure of tissue oxygen  (PbrO2, in mmHg) (a) and laser speckle perfusion units (b) in the normal blood 
pressure group (NBP) and low blood pressure group (LBP). Whiskers extend a maximum of 1.5× the interquartile range. The value for ischaemic 
threshold is shown (dashed line). Experimental time points: PCB pre-caval block, PR-1 initial baseline for propofol-remifentanil TIVA, PR-2 immediately 
before dexmedetomidine administration, PRD following propofol–remifentanil–dexmedetomidine TIVA. Significant differences from either the 
ischaemia limit (vertical bars) or between timepoints (horizontal bars) are shown
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pressure, since it could result in decreased cerebral oxy-
genation. Further and larger studies are required for con-
firmation of these results.
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